HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors (clinicaltrials.gov) - Jul 31, 2025 - P=N/A | N=19 | Terminated | Sponsor: Alaunos Therapeutics | Previously enrolled participants completed TCR001-002 by 23 Mar 2023. Not stopped for safety reasons.
Enrollment change • IO biomarker • Trial termination • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Endometrial Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor
|